問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
Principal Investigator
顏家瑞
下載
2015-09-15 - 2019-09-30
Condition/Disease
Test Drug
Participate Sites13Sites
Terminated11Sites
未分科
2020-08-01 - 2024-11-29
Participate Sites2Sites
Recruiting2Sites
2020-11-01 - 2030-08-22
Participate Sites4Sites
Recruiting4Sites
2019-11-30 - 2026-09-30
Participate Sites9Sites
Recruiting9Sites
2021-03-01 - 2026-12-30
Participate Sites6Sites
Recruiting6Sites
2022-01-01 - 2026-12-31
2016-11-01 - 2025-12-31
Participate Sites12Sites
Division of Hematology & Oncology
2013-10-01 - 2016-12-31
Terminated2Sites
2013-03-01 - 2020-12-31
Participate Sites5Sites
Terminated5Sites
2018-03-01 - 2023-12-31
Hepatocellular Carcinoma (HCC)
Atezolizumab; Bevacizumab; Sorafenib
全部
